Liver Cancer Treatment in Hyderabad — Expert Oncology Care Across 7 Locations

Liver Cancer in Hyderabad — What You Need to Know

Liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death, according to the World Health Organisation (WHO). In India — and particularly across Telangana and Andhra Pradesh — its incidence is significantly influenced by the high prevalence of chronic Hepatitis B and Hepatitis C infections, both of which are major risk factors for hepatocellular carcinoma (HCC), the most common form of primary liver cancer — explained clearly in this Mayo Clinic overview of liver cancer.

Liver cancer is broadly categorised into two types: primary liver cancer, which originates in the liver itself, and secondary (metastatic) liver cancer, which spreads to the liver from another organ such as the colon, breast, or lung. Both require specialist oncology management — and both are treated at CION Cancer Clinics.

The most important factor in liver cancer treatment outcomes is access to a specialist centre with the full range of locoregional, surgical, and systemic treatment options — and a multidisciplinary team that reviews every case before any decision is made.

Types of Liver Cancer We Treat

Not all liver cancers behave the same way. CION's tumour board evaluates every patient's diagnosis at the cellular and molecular level so treatment is tailored precisely to the subtype.

Symptoms of Liver Cancer

Liver cancer often produces no symptoms in its early stages — which is why surveillance in high-risk patients is critical. As the disease progresses, the following signs may appear:

• Jaundice — yellowing of the skin and whites of the eyes, indicating impaired bile processing
• Pain or swelling in the upper right abdomen
• Unexplained and unintentional weight loss
• Loss of appetite and persistent nausea
• Ascites — fluid accumulation in the abdomen causing visible distension
• Fatigue and general weakness
• A palpable lump or fullness in the right side of the abdomen
• Pale or chalky stools and dark urine

These symptoms are not exclusive to liver cancer and may indicate other liver conditions. A specialist evaluation — including an alpha-fetoprotein (AFP) blood test and imaging — is essential to confirm the diagnosis. Speak to a CION liver oncologist if you have symptoms or known risk factors.

Risk Factors and the Hepatitis B/C Connection

Understanding your personal risk is critical — particularly for residents of Telangana and Andhra Pradesh, where Hepatitis B and C prevalence is among the highest in India. Key risk factors for liver cancer include:

• Chronic Hepatitis B infection — the single most important preventable risk factor for HCC; responsible for approximately 50% of all HCC cases worldwide
• Chronic Hepatitis C infection — leads to liver cirrhosis which significantly elevates HCC risk
• Liver cirrhosis from any cause — alcohol-related liver disease, NASH/NAFLD, autoimmune hepatitis
• Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome — rising rapidly in urban Hyderabad due to changing dietary habits
• Chronic alcohol use
• Type 2 diabetes and obesity
• Aflatoxin exposure — from contaminated grains and groundnuts, particularly relevant in rural Telangana/AP
• Family history of liver cancer or hereditary conditions (haemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency)

If you have any of these risk factors, regular liver function tests and ultrasound surveillance every 6 months are recommended. Early-stage HCC detected through surveillance has significantly better treatment outcomes than symptomatically-diagnosed disease.

Why Patients Choose CION for Liver Cancer Treatment in Hyderabad

Fifteen reasons our patients pick CION — across volume, surgical and locoregional expertise, current systemic therapy, and supportive care.

Liver Cancer Diagnosis at CION

CION's diagnostic pathway integrates blood markers, advanced imaging, and biopsy where required to confirm diagnosis, determine cancer type, and accurately stage the disease before any treatment decision is made.

Blood Tests

• Alpha-fetoprotein (AFP) — elevated in 50–70% of HCC patients; used alongside imaging for diagnosis and treatment monitoring
• Liver function tests (LFTs) — assess underlying liver reserve, critical for determining treatment eligibility
• Hepatitis B and C serology — standard workup for every liver cancer patient

Imaging

• Ultrasound — first-line screening tool; identifies liver lesions and ascites
• Triple-phase CT Scan — the gold standard for HCC diagnosis; characteristic arterial enhancement followed by portal venous washout is diagnostic without biopsy in most cases
• MRI with liver-specific contrast — for indeterminate lesions on CT; most sensitive imaging modality for small HCCs
• PET-CT — for staging cholangiocarcinoma and secondary liver cancer; less useful for HCC

Biopsy

For most HCC cases meeting radiological criteria, biopsy is not required for diagnosis. A biopsy is performed for atypical imaging findings, suspected cholangiocarcinoma, or when histological confirmation is required for systemic therapy eligibility. CION performs image-guided core needle biopsies where clinically indicated.

BCLC Staging and Treatment Options

The Barcelona Clinic Liver Cancer (BCLC) staging system is the internationally recognised framework for liver cancer treatment decisions. It considers tumour burden, liver function (Child-Pugh score), and the patient's performance status together. CION's tumour board uses BCLC staging as the foundation for every liver cancer treatment plan.

Note: Treatment selection always accounts for individual patient factors including comorbidities, liver reserve, and patient preference. The table above reflects standard NCCN/BCLC recommendations and is subject to tumour board review for every case.

Liver Cancer Treatment at CION Cancer Clinics

CION follows NCCN (National Comprehensive Cancer Network) and ESMO treatment protocols for all liver cancer subtypes. Every patient's treatment plan is reviewed and approved by our multidisciplinary tumour board before initiation.

Surgical Oncology — Liver Resection

Surgical resection — partial hepatectomy — is the gold standard curative treatment for early-stage HCC in patients with adequate liver function and no underlying cirrhosis. CION's surgical oncology team performs both open and laparoscopic (minimally invasive) liver resection.

• Partial Hepatectomy (Open) — removal of the tumour-bearing liver segment; indicated for larger lesions or tumours near major vessels requiring careful dissection
• Laparoscopic Liver Resection — minimally invasive approach offering reduced blood loss, shorter hospital stay, and faster recovery
• Anatomical vs Non-anatomical Resection — chosen based on tumour location, liver segment anatomy, and remaining liver volume

Liver Transplant — Referral and Coordination

Liver transplantation replaces the diseased liver with a healthy donor liver and simultaneously eliminates the underlying cirrhosis — the leading cause of post-surgical liver failure. It is the treatment of choice for patients meeting the Milan Criteria: a single tumour ≤5cm, or up to 3 tumours each ≤3cm, with no vascular invasion or extrahepatic spread.

CION does not perform liver transplants in-house. Patients who meet transplant eligibility criteria are referred to NABH-accredited transplant centres with established surgical programmes. CION manages the complete patient journey — pre-transplant workup, oncology coordination, and post-transplant oncology follow-up — ensuring continuity of care.

Locoregional Therapy — TACE, TARE & Ablation

These procedures target the tumour directly while minimising systemic side effects.

• TACE (Transarterial Chemoembolization) — the standard of care for intermediate-stage (BCLC B) HCC. CION performs both conventional TACE and drug-eluting bead TACE (DEB-TACE).
• TARE / SIRT (Transarterial Radioembolization) — Yttrium-90 microspheres delivered via the hepatic artery; an option for patients unsuitable for TACE or with portal vein involvement
• Radiofrequency Ablation (RFA) — heat-based destruction of small HCCs (typically <3cm) in patients not eligible for surgery
• Microwave Ablation (MWA) — similar to RFA with faster ablation times; effective for lesions near large blood vessels
• Percutaneous Ethanol Injection (PEI) — used in select cases where thermal ablation is technically challenging

Radiation Therapy

Radiation therapy for liver cancer requires careful technique due to the liver's radiosensitivity. CION's radiation oncology team uses advanced methods to deliver precise, targeted radiation while protecting surrounding healthy liver tissue.

• Stereotactic Body Radiation Therapy (SBRT) — high-dose, precisely targeted radiation in a small number of fractions; effective for patients not suitable for surgery or ablation
• IMRT (Intensity-Modulated Radiation Therapy) — used for cholangiocarcinoma and select HCC cases
• External Beam Radiation Therapy (EBRT) — for palliative pain control in advanced liver cancer

Advanced Systemic Therapy for Liver Cancer — What Most Hospital Pages Don't Tell You

For patients with advanced or metastatic HCC (BCLC Stage C) who are not candidates for locoregional therapy, systemic treatment has been transformed over the past five years. CION's medical oncology team delivers current NCCN first-line and second-line protocols — including therapies that no other hospital treatment page in Hyderabad currently describes.

First-Line: Atezolizumab + Bevacizumab (Tecentriq + Avastin)

The current NCCN and ESMO preferred first-line systemic therapy for advanced HCC. This combination pairs atezolizumab — a PD-L1 immune checkpoint inhibitor that releases the immune system's brakes — with bevacizumab, an anti-angiogenic agent that restricts the tumour's blood supply. The IMbrave150 trial demonstrated significantly improved overall survival and progression-free survival compared to sorafenib alone, establishing this combination as the new standard of care. CION delivers this regimen with regular liver function and imaging monitoring throughout treatment.

Alternative First-Line: Sorafenib and Lenvatinib

For patients with contraindications to bevacizumab (e.g., varices, bleeding risk), sorafenib or lenvatinib remain effective first-line options. Both are oral multikinase inhibitors that inhibit tumour angiogenesis and cell proliferation. CION monitors for known side effects including hand-foot syndrome, hypertension, and fatigue, with dose adjustments as needed.

Second-Line Systemic Therapy

• Regorafenib — oral multikinase inhibitor for patients who progressed on sorafenib
• Cabozantinib — targets multiple receptor tyrosine kinases; effective second-line option
• Ramucirumab — anti-VEGFR2 antibody; indicated for patients with AFP ≥400 ng/mL after sorafenib
• Pembrolizumab — immune checkpoint inhibitor as second-line option for select patients

Systemic Therapy for Cholangiocarcinoma

Gemcitabine + cisplatin remains the standard first-line chemotherapy for advanced cholangiocarcinoma. Patients with IDH1 mutations may be eligible for ivosidenib. FGFR2 fusion-positive intrahepatic cholangiocarcinoma can be treated with pemigatinib or infigratinib. CION performs molecular profiling on all advanced cholangiocarcinoma cases to assess targeted therapy eligibility.

Multidisciplinary Tumour Board — Every Case Reviewed by a Team

Liver cancer management involves one of the most complex intersections of specialties in oncology — surgical oncology, medical oncology, radiation oncology, and interventional radiology must all contribute to the treatment decision. At CION, every liver cancer case is reviewed by a multidisciplinary tumour board before treatment begins, ensuring:

• Accurate BCLC staging and treatment-stage alignment
• Assessment of liver function reserve (Child-Pugh score) before any intervention
• Coordination between surgical resection and locoregional therapy (e.g., downstaging with TACE before surgery)
• Transplant eligibility evaluation and timely referral where applicable
• Alignment with current NCCN and ESMO evidence-based guidelines
• Digital coordination across all 7 Hyderabad locations for consistent, uninterrupted care

Liver Cancer Treatment Cost in Hyderabad

The cost of liver cancer treatment in Hyderabad varies significantly based on the cancer type, stage, and the specific treatment approach recommended by the tumour board. The following ranges reflect current market data:

Costs are indicative. A personalised cost estimate is provided following your initial oncology consultation at CION.

Financial Support Options

• Aarogyasri Scheme — cashless treatment coverage for eligible Telangana residents (White Ration Card holders). CION is Aarogyasri empanelled.
• EMI Facility — flexible instalment-based payment options available for all patients.
• Private Health Insurance — CION works with all major TPAs for cashless hospitalisation.

Liver Cancer Care Near You — In Hyderabad & Beyond

CION operates 35+ centres across Telangana and Andhra Pradesh. Find your nearest liver cancer specialist or explore care options in your city.

Liver Cancer Care in Hyderabad — by Location

Liver Cancer Care Beyond Hyderabad

Travelling for treatment? We may have a centre right where you are — across Telangana and Andhra Pradesh.

Not seeing your city? Call 18002028726 — we'll connect you to the nearest CION centre or arrange a teleconsultation.

Get a Free Written Second Opinion from CION's Tumour Board

Our multidisciplinary team reviews your imaging, AFP, and pathology — before any surgery, TACE, or systemic therapy begins.

Frequently Asked Questions

Common questions about liver cancer treatment in Hyderabad — answered by CION's oncology team.

Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.